Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of sacituzumab govitecan versus standard treatment in previously treated extensive-stage small cell lung cancer
MOH_2025-05-13_014088Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Mar 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing Sacituzumab Govitecan with Topotecan (2 arms). Primary endpoints: Objective response rate and Overall survival. Started Mar 2025; status: active, not recruiting.
02
Drugs
sacituzumab govitecantopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2025-05-13_014088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-05-13_014088.